drugset / Trial / NCT01146561

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

NCT01146561

Phase 2 Terminated 2 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

Tanezumab is effective in reducing the pain associated with chronic pancreatitis.

Timeline

Start
2010-10-13
Primary completion
2011-03-22
Completion
2011-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 20 mg Subcutaneous

Indications